INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 41h ago
HOUSE PTR1h ago
SEC 13F1h ago
ROBINHOOD CHAIN1h ago
Corporate insider
TE

Tamayo Louis Edward

Chief Financial OfficerCIK 0002083206

EDGAR filingsOpen in network
Disclosed transactions6
Buys / sells0 / 2
Max Insider Score36
Connections1with evidence

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
5
TE
Tamayo Louis EdwardChief Financial Officer
LXEOLexeo Therapeutics, Inc.
Grant or award
A—
54.8K sh
Sep 24, 2026Sep 28, 2026
traded Sep 24, 2026
+4dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    Lexeo Therapeutics, Inc.Chief Financial Officer · Feb 6, 2026
27
TE
Tamayo Louis EdwardChief Financial Officer
LXEOLexeo Therapeutics, Inc.
Open-market sale
SELL
$20K
4,117 sh
Aug 18, 2026
Aug 19, 2026
traded Aug 18, 2026
+1d
SEC FORM 4

Evidence

13
TE
Tamayo Louis EdwardChief Financial Officer
LXEOLexeo Therapeutics, Inc.
Grant or award
A—
12.0K sh
Jun 29, 2026Jul 1, 2026
traded Jun 29, 2026
+2dSEC FORM 4

Evidence

36
TE
Tamayo Louis EdwardChief Financial Officer
LXEOLexeo Therapeutics, Inc.
Open-market sale
SELL$21K
4,641 sh
Jul 1, 2026Jul 1, 2026
traded Jul 1, 2026
+0dSEC FORM 4

Evidence

21
TE
Tamayo Louis EdwardChief Financial Officer
LXEOLexeo Therapeutics, Inc.
Grant or award
A—
44.7K sh
Feb 4, 2026Feb 6, 2026
traded Feb 4, 2026
+2dSEC FORM 4

Evidence

9
TE
Tamayo Louis EdwardChief Financial Officer
LXEOLexeo Therapeutics, Inc.
Grant or award
A—
226.7K sh
Feb 4, 2026Feb 6, 2026
traded Feb 4, 2026
+2dSEC FORM 4

Evidence